Clinical Trial

PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The objective of this study is to construct a noninvasive approach using radiolabbled peptide 68Ga-cPP-BCH PET/CT to detect the PD-L1 expression of tumor lesion in patients with lung cancer, melanoma and other solid tumor to identify patients benefiting from anti-PD-(L)1 treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-24.
Trial Details
NCT Number NCT07442292
Lead Sponsor Peking University Cancer Hospital & Institute
Conditions Lung Cancer (NSCLC), Lung Cancer (SCLC), Melanoma (Skin Cancer), Melanoma Metastatic, PD-L1, PET / CT
Enrollment 40 participants
Start Date 2026-02
Primary Completion 2026-12 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-05